Fact is, government run public health does look at numbers at the end of the day. A medicine that increases "value" (however you define that) more than it costs is more likely to get gov funding.
Turning away from the elephant in the room because it is "vile" doesn't help anyone and just entrenches the status quo.
You're looking at this in a very American Centric way, a lot of other countries figure out how medicines for very low costs. When that happens the numbers change a lot.
Turning away from the elephant in the room because it is "vile" doesn't help anyone and just entrenches the status quo.